Royalty Pharma plc Class A Ordinary Shares RPRX
$58.60
+0.07%
at last close
Analyst Consensus
- Consensus Rating
- Buy (6 Buy · 0 Hold · 0 Sell)
- Average Price Target
- $59.17
- Implied Upside
- +1.0%
- Price Target Range
- $42.00 – $66.00
- Analysts (12 mo)
- 6
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-08-07 | JP MorganChris Schott |
Maintains | Overweight | $58 → $62 |
| 2026-07-13 | TD CowenSteve Scala |
Maintains | Buy | $50 → $65 |
| 2026-05-07 | CitigroupGeoff Meacham |
Maintains | Buy | $50 → $66 |
| 2026-05-07 | JP MorganChris Schott |
Maintains | Overweight | $50 → $58 |
| 2026-04-21 | UBSAshwani Verma |
Maintains | Buy | $51 → $57 |
| 2026-04-10 | Morgan StanleyTerence Flynn |
Maintains | Overweight | $61 → $63 |
| 2026-01-30 | UBSAshwani Verma |
Upgrades | Neutral → Buy | $38 → $49 |
| 2026-01-27 | CitigroupGeoff Meacham |
Maintains | Buy | $48 → $50 |
| 2025-12-11 | TD CowenSteve Scala |
Maintains | Buy | $42 → $45 |
| 2025-10-10 | Morgan StanleyTerence Flynn |
Maintains | Overweight | $55 → $54 |
| 2025-09-30 | Goldman SachsAsad Haider |
Initiates coverage on | Buy | $42 |
| 2025-07-22 | CitigroupGeoff Meacham |
Maintains | Buy | $40 → $42 |
| 2025-07-10 | Morgan StanleyTerence Flynn |
Maintains | Overweight | $51 → $54 |
| 2024-10-25 | CitigroupAndrew Baum |
Maintains | Buy | $60 → $40 |
| 2024-08-14 | Goldman SachsChris Shibutani |
Maintains | Buy | $50 → $51 |
| 2024-07-11 | Morgan StanleyTerence Flynn |
Maintains | Overweight | $48 → $51 |
| 2024-06-03 | UBSAshwani Verma |
Downgrades | Buy → Neutral | $28 |
| 2024-04-12 | B of A SecuritiesGeoff Meacham |
Maintains | Buy | $40 → $38 |
| 2024-02-20 | JP MorganChris Schott |
Maintains | Overweight | $45 → $42 |
| 2024-02-20 | Goldman SachsChris Shibutani |
Maintains | Buy | $56 → $50 |
| 2023-11-09 | Morgan StanleyTerence Flynn |
Maintains | Overweight | $54 → $57 |
| 2023-10-11 | Morgan StanleyTerence Flynn |
Maintains | Overweight | $53 → $54 |
| 2023-08-09 | Morgan StanleyTerence Flynn |
Maintains | Overweight | $52 → $53 |
| 2023-07-11 | Morgan StanleyTerence Flynn |
Reiterates | Overweight | $52 |
| 2023-05-10 | Morgan StanleyTerence Flynn |
Maintains | Overweight | $50 → $52 |
| 2023-04-10 | Morgan StanleyTerence Flynn |
Maintains | Overweight | $48 → $50 |
| 2023-04-06 | Tigress FinancialIvan Feinseth |
Reiterates | Buy | $57 → $60 |
| 2023-02-16 | UBSAshwani Verma |
Maintains | Buy | $51 → $48 |
| 2022-12-06 | Morgan StanleyTerence Flynn |
Maintains | Overweight | $54 → $51 |
| 2022-11-09 | Morgan StanleyTerence Flynn |
Maintains | Overweight | $51 → $54 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $58.60
- Market Cap
- $26.37 billion
- 52-Week Range
- $34.08 – $60.44
- Average Volume
- 2.85 million shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.